Patents Examined by Janet L Coppins
  • Patent number: 10799478
    Abstract: The present invention provides a method of treating symptoms associated with Androgen Deprivation Therapy comprising administering to a patient in need of such treatment an effective amount of a compound of Formula I: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: October 13, 2020
    Assignee: Eli Lilly and Company
    Inventors: Rachel Nicole Richey, Hannah Yu
  • Patent number: 10792268
    Abstract: The ketogenic diet (KD) has therapeutic implications in many disease states. It was hypothesized ketone precursor supplementation would elevate blood ketone levels to therapeutic ranges (2-7 mM) without need for dietary restriction. The effects of ketogenic agents were tested on blood glucose, ketones, and lipids with a 28-day dose escalation study in male Sprague-Dawley rats: R,S-1,3-Butandiol (BD), acetoacetate ketone ester (KE), and control (H2O) (n?8). Days 1-28, rats received a daily 5 g/kg intragastric gavage, based on previous toxicology studies. Once weekly, whole blood samples (10 ?l) were acquired for analysis of glucose and ?HB at 0, 0.5, 1, 4, 8, and 12 hours after test substance administration, or until ?HB returned to baseline. At day 1 and 28, 10 ?L of whole blood were collected to measure triglycerides, total cholesterol, and HDL concentration. Significant elevation of blood ketone was observed with a significant inverse relationship with blood glucose for the duration of the experiment.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: October 6, 2020
    Assignee: University of South Florida
    Inventors: Dominic Paul D'Agostino, Shannon Kesl
  • Patent number: 10786500
    Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: September 29, 2020
    Assignee: ASTELLAS PHARMA INC.
    Inventors: Masakazu Miyazaki, Ryohei Ishiba, Yuki Takaishi, Fumiaki Uejo
  • Patent number: 10786479
    Abstract: The invention provides a method of inhibiting the conversion of carnitine to trimethylamine (TMA) and lowering TMAO in an individual comprising administering to the individual one or more compositions comprising a compound set forth in Formula (I): Wherein the compound is administered in an amount effective to inhibit conversion of carnitine to TMA in the individual.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: September 29, 2020
    Assignees: The Procter & Gamble Company, The Cleveland Clinic Foundation
    Inventors: Stanley Leon Hazen, Jose Carlos Garcia-Garcia, George Franklin Gerberick, John August Wos, David Thomas Stanton, Thomas Alfred Inglin, Michael Reilly, Angela Jane Deutsch, Jodie Michele Reed, David Blair Cody
  • Patent number: 10780078
    Abstract: Described herein, inter alia, are compositions and methods for modulating mu opioid receptor activity.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: September 22, 2020
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, FRIEDRICH-ALEXANDER-UNIVERSITÄT, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Brian K. Shoichet, Anat Levit, Aashish Manglik, Brian Kobilka, Peter Gmeiner, Harald Hübner, Daniela Gisela Dengler
  • Patent number: 10780072
    Abstract: The invention provides one or more methods of inhibiting the conversion of choline to trimethylamine (TMA) and lowering TMAO in an individual comprising administering to the individual one or more compositions comprising a compound set forth in Formula (I): wherein the compound is administered in an amount effective to inhibit formation of trimethylamine (TMA) from choline in the individual.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: September 22, 2020
    Assignees: The Procter & Gamble Company, The Cleveland Clinic Foundation
    Inventors: Stanley Leon Hazen, Jose Carlos Garcia-Garcia, George Franklin Gerberick, John August Wos, David Thomas Stanton, Thomas Alfred Inglin, Michael Reilly, Angela Jane Deutsch, Jodie Michele Reed, David Blair Cody
  • Patent number: 10772858
    Abstract: This disclosure relates to benzhydrol derivatives for managing conditions related to the Hypoxia Inducible Factor (HIF) pathway such as uses in treating cancer. In certain embodiment, the disclosure contemplates compounds and pharmaceutical compositions. In certain embodiment, the disclosure contemplates compounds disclosed herein as prodrugs, optionally substituted with one or more substituents, derivatives, or salts thereof.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: September 15, 2020
    Assignees: GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC., EMORY UNIVERSITY
    Inventors: Binghe Wang, Erwin Van Meir, Jalisa Holmes Ferguson, Stefan Kaluz, Xingyue Ji
  • Patent number: 10765660
    Abstract: A pharmaceutical composition for the prevention and treatment of cancer with specific flavanoid-based compounds selected from among the groups of Flavone, Flavanone and Flavanol, a method for the prevention and treatment of cancer and inflammation using the specific flavonoid-based pharmaceutical compositions, a method for isolating the flavonoid-based pharmaceutical compositions from raw plant material, and a method for synthesizing said specific flavonoid-based pharmaceutical compositions.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: September 8, 2020
    Inventors: Henry Lowe, Ngeh J. Toyang, Joseph Bryant
  • Patent number: 10758505
    Abstract: The invention provides compositions and unit dosage forms that are effective to improve sexual performance. Such compositions and unit dosage forms are useful to increase duration of sexual intercourse, satisfaction with sexual intercourse, and improve erectile function in men.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: September 1, 2020
    Assignee: INNOVUS PHARMACEUTICALS, INC.
    Inventor: Bassam Damaj
  • Patent number: 10759791
    Abstract: Disclosed are compounds that are shown to inhibit the biological activity of nitric oxide synthases (NOSs). Also disclosed are pharmaceutical compositions comprising the compounds, and methods of using the compounds and pharmaceutical compositions for treating a subject in need thereof. Because the disclosed compounds are shown to inhibit the activity of nitric oxide synthases (NOSs), the disclosed compounds and pharmaceutical compositions may be utilized in methods for treating a subject having or at risk for developing a disease or disorder that is associated with NOS activity.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: September 1, 2020
    Assignee: Northwestern University
    Inventors: Richard B. Silverman, Heng-Yen Wang, Yajuan Qin, Fengwei Zou, Soo Sung Kang, Qing Jing
  • Patent number: 10758515
    Abstract: The present invention provides a method of treating symptoms associated with Androgen Deprivation Therapy comprising administering to a patient in need of such treatment an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: September 1, 2020
    Assignee: Eli Lilly and Company
    Inventor: Charles Thomas Benson
  • Patent number: 10751335
    Abstract: The invention provides—opioid receptor agonists that are analgesic agents and that promote diminished side effects relative to a comparably effective dose of morphine. The side effects that are absent or attenuated include one or more of the following: constipation, respiratory depression, tolerance, dependence, nausea, confusion, sedation, hypotension, and post-treatment withdrawal symptoms.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: August 25, 2020
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Thomas D. Bannister, Laura M. Bohn, Cullen L. Schmid
  • Patent number: 10736861
    Abstract: Ketogenic compositions including a beta-hydroxybutyrate (BHB) mixed salt are formulated to induce or sustain ketosis in a subject to which the ketogenic compositions are administered. The BHB mixed salt is formulated to provide a biologically balanced set of cationic electrolytes, and is formulated to avoid detrimental health effects associated with imbalanced electrolyte ratios. A ketogenic composition includes BHB salts of at least sodium, potassium, calcium, and magnesium. The BHB salts may also include at least other component such as a BHB compound containing other cations, such as transition metal cations (e.g., zinc or iron), a BHB-amino acid salts, medium chain fatty acid source, vitamin D3, flavorant, or other excipient.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: August 11, 2020
    Assignee: AXCESS GLOBAL SCIENCES, LLC
    Inventor: Gary Millet
  • Patent number: 10736897
    Abstract: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, isotopic form or prodrug thereof, wherein R1, R2a, R2b, R2c, R3a, R3b, R4a, R4b, L1, L2, E, X, Y, Z, m1 and m2 are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: August 11, 2020
    Assignee: ARAXES PHARMA LLC
    Inventors: Liansheng Li, Jun Feng, Tao Wu, Yuan Liu, Yi Wang, Pingda Ren, Yi Liu
  • Patent number: 10716788
    Abstract: The present invention provides methods of treating MS using pyrimidine and pyridine compounds which are inhibitors of Bruton's tyrosine kinase (BTK).
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: July 21, 2020
    Assignee: Merck Patent GmbH
    Inventor: Tammy Dellovade
  • Patent number: 10709681
    Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: July 14, 2020
    Assignee: UNIVERSITY OF MISSISSIPPI
    Inventors: Mahmoud A. ElSohly, Soumyajit Majumdar, Waseem Gul, Mohammad Khalid Ashfaq, Kenneth Joseph Sufka, Hannah Marie Harris
  • Patent number: 10702532
    Abstract: Disclosed herein, inter alia, are acyclic nucleotide analogs and methods of using an acyclic nucleotide analog for treating and/or ameliorating a papillomavirus infection.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: July 7, 2020
    Assignee: The Regents of the University of California
    Inventors: Karl Y. Hostetler, James R. Beadle, Nadejda Valiaeva
  • Patent number: 10682353
    Abstract: The present disclosure provides a method of treating a patient with refractory or resistant cancer by administering a therapeutically effective amount of a compound of formula (I), such as Varlitinib, or an enantiomer thereof or a pharmaceutically acceptable salt of any one of the same. Also provided is a compound of formula (I) for use in the treatment of resistant or refractory cancer and use of a compound of formula (I) for the manufacture of a medicament for the treatment of resistant or refractory cancer.
    Type: Grant
    Filed: September 5, 2016
    Date of Patent: June 16, 2020
    Assignee: ASLAN Pharmaceuticals PTE LTD
    Inventors: Bertil Lindmark, Lisa Ooi
  • Patent number: 10682335
    Abstract: The present invention discloses use of butylidenephthalide (Bdph), a method of using the same, and a method for preparing a pharmaceutical composition containing the same. Because Bdph has the capability of promoting the hair growth and reducing the ?-amyloid protein (A?) level in nerve cells, the efficacy of improving the health and appearance of a subject can be achieved by administrating an effective amount of Bdph to the subject. Specifically, the Bdph has the efficacy of preventing or treating neurodegenerative diseases such as Alzheimer's disease caused by excessive build up of A? in the cells, and as an active ingredient in a topical composition, the Bdph is effective in promoting the hair growth at the site where the Bdph is administered.
    Type: Grant
    Filed: July 28, 2014
    Date of Patent: June 16, 2020
    Assignee: EVERFRONT BIOTECH INC.
    Inventors: Hong-Lin Su, Chia-Yu Chang, Shiaw-Min Hwang, Huai-En Lu, Horng-Jyh Harn, Shinn-Zong Lin, Ping-Shan Lai
  • Patent number: 10675257
    Abstract: The present invention relates to a composition for use in treating a glioma or ameliorating the effects of a glioma, particularly glioblastoma, wherein said composition comprises a first active agent selected from the group consisting of a compound of formula (I), or a pharmaceutically acceptable salt thereof, (I) and a second active agent, which is temozolomide, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: June 9, 2020
    Assignee: INFLECTIS BIOSCIENCE
    Inventors: Philippe Guedat, Pierre Miniou